

INFORMATION DISCLOSURE STATEMENT

Applicant : Sallberg, et al.
App. No : 10/817,591
Filed : April 2, 2004
For : VACCINES CONTAINING
RIBAVIRIN AND METHODS OF USE
THEREOF
Examiner : Bao Q. Li
Art Unit : 1648

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed is a PTO/SB/08 Equivalent listing 139 references. References numbered 1 - 139 are of record in U.S. patent application No.09/929,955, filed August 15, 2001, which is relied upon for an earlier filing date under 35 U.S.C. § 120. Accordingly, copies of references numbered 1 - 139 are not submitted pursuant to 37 C.F.R. § 1.98(d).

This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required. If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.


Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: August 8, 2005

By: 

Eric S. Fufman
Registration No. 45,664
Attorney of Record
Customer No. 20,995
(619) 235-8550



INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application No.	10/817,591
		Filing Date	April 2, 2004
		First Named Inventor	Sallberg et al.
		Art Unit	1648
(Multiple sheets used when necessary)		Examiner	Bao Q. Li
SHEET 1 OF 7		Attorney Docket No.	TRIPEP.23AUS2C1

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	1	4,946,778	08/07/1990	Ladner et al.	
	2	4,950,647	08/21/90	Robins et al.	
	3	5,350,671	09/27/94	Houghton et al.	
	4	5,371,017	12/06/1994	Houghton et al.	
	5	5,372,928	12/13/94	Miyamura et al.	
	6	5,585,258	12/17/1996	Houghton et al.	
	7	5,589,466	12/31/1996	Felgner et al.	
	8	5,597,691	01/28/1997	Houghton et al.	
	9	5,670,152	09/23/97	Weiner et al.	
	10	5,670,153	09/23/97	Weiner et al.	
	11	5,679,342	10/21/1997	Houghton et al.	
	12	5,683,864	11/04/97	Houghton et al.	
	13	5,698,390	12/16/1997	Houghton et al.	
	14	5,712,087	01/27/1998	Houghton et al.	
	15	5,712,088	01/27/1998	Houghton et al.	
	16	5,712,145	01/27/98	Houghton et al.	
	17	5,714,596	02/03/1998	Houghton et al.	
	18	5,728,520	03/17/98	Weiner et al.	
	19	5,756,312	03/26/98	Weiner et al.	
	20	5,767,097	06/16/98	Tam	
	21	5,856,437	01/05/99	Miyamura et al.	
	22	5,863,719	01/26/1999	Houghton et al.	
	23	5,871,903	02/16/99	Miyamura et al.	
	24	5,885,799	03/23/1999	Houghton et al.	
	25	5,932,556	08/03/1999	Tam et al.	
	26	5,942,234	08/24/99	Ralston et al.	
	27	5,959,092	08/24/1999	Ralston et al.	
	28	5,968,775	10/18/1999	Houghton et al.	
	29	5,989,905	11/23/99	Houghton et al.	

Examiner Signature	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/817,591
	Filing Date	April 2, 2004
	First Named Inventor	Sallberg et al.
	Art Unit	1648
(Multiple sheets used when necessary)	Examiner	Bao Q. Li
SHEET 2 OF 7	Attorney Docket No.	TRIPEP.23AUS2C1

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	30	6,027,729	02/22/2000	Houghton et al.	
	31	6,056,961	05/02/2000	Lavie et al.	
	32	6,060,068	05/09/00	Doyle et al.	
	33	6,063,380	05/16/2000	Chedid et al.	
	34	6,063,772	05/16/00	Tam	
	35	6,071,693	06/06/00	Cha et al.	
	36	6,074,816	06/13/2000	Houghton et al.	
	37	6,074,846	06/13/2000	Ralston et al.	
	38	6,074,852	06/13/2000	Ralston et al.	
	39	6,096,541	08/01/2000	Houghton et al.	
	40	6,130,326	10/10/2000	Ramasamy et al.	
	41	6,150,087	11/21/2000	Chien	
	42	6,150,337	11/21/2000	Tam	
	43	6,171,782	01/09/2001	Houghton et al.	
	44	6,190,864	02/20/01	Cha et al.	
	45	6,194,140	02/27/01	Houghton et al.	
	46	6,214,583	04/10/01	Cha et al.	
	47	6,235,888	05/22/2001	Pachuk et al.	
	48	6,274,148	08/14/2001	Ralston et al.	
	49	6,297,370	10/02/2001	Cha et al.	
	50	6,303,292	10/16/2001	Weiner et al.	
	51	6,312,889	11/06/2001	Houghton et al.	
	52	6,514,731	02/04/03	Valenzuela et al.	
	53	6,541,011	04/01/03	Punnonen et al.	
	54	6,555,114	04/29/03	Leroux-Roels et al.	
	55	2002/0004048	01/10/2002	Ralston et al.	
	56	2002/0165172 A1	11/07/02	Sallberg et al.	
	57	2002/0183508 A1	12/05/02	Maertens et al.	
	58	2002/0187945 A1	12/12/02	Tam	

Examiner Signature	Date Considered
--------------------	-----------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/817,591
	Filing Date	April 2, 2004
	First Named Inventor	Sallberg et al.
	Art Unit	1648
(Multiple sheets used when necessary)	Examiner	Bao Q. Li
SHEET 3 OF 7	Attorney Docket No.	TRIPEP.23AUS2C1

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	59	2003/0007977	01/09/03	Wheeler et al.	
	60	2003/0008274	01/09/03	Maertens et al.	
	61	2003/0032005	02/13/03	Maertens et al.	
	62	2003/0044774	03/06/03	Valenzuela et al.	
	63	2003/0064360	04/03/03	Maertens et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹
	64	EP 0 318 216	08/29/01	European Patent Office		
	65	EP 0 388 232	09/19/90	European Patent Office		
	66	EP 0 398 748	01/09/02	European Patent Office		
	67	EP 0 414 475	02/27/91	European Patent Office		
	68	EP 0 450 931	06/12/96	European Patent Office		
	69	EP 0 543 924	06/18/97	European Patent Office		
	70	EP 0 556 292	12/29/99	European Patent Office		
	71	EP 0 693 687	07/28/99	European Patent Office		
	72	EP 0 842 947	05/20/98	European Patent Office		
	73	EP 1 034 785	09/13/00	European Patent Office		
	74	WO 00/44388	08/03/00	WIPO		
	75	WO 02/13855	02/21/02	WIPO		
	76	WO 02/14362	02/21/02	WIPO		
	77	WO 91/15575	10/17/91	WIPO		
	78	WO 92/19743	11/12/92	WIPO		
	79	WO 93/00365	01/07/93	WIPO		
	80	WO 93/06126	04/01/93	WIPO		
	81	WO 94/16737	08/07/94	WIPO		
	82	WO 96/28162	09/19/96	WIPO		
	83	WO 97/12043	04/03/97	WIPO		

Examiner Signature	Date Considered
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/817,591
	Filing Date	April 2, 2004
	First Named Inventor	Sallberg et al.
	Art Unit	1648
(Multiple sheets used when necessary)	Examiner	Bao Q. Li
SHEET 4 OF 7	Attorney Docket No.	TRIPEP.23AUS2C1

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹
	84	WO 97/26883	07/31/97	WIPO		
	85	WO 98/16184	04/23/98	WIPO		
	86	WO 98/16186	04/23/98	WIPO		
	87	WO 98/30223	07/16/98	WIPO		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	88	AASLD Abstracts 940, "Hepatitis C Virus NS5A Sequence Configuration does not Predict Response to Induction Interferon Plus Ribavirin," <i>Hepatology</i> , p. 394A (2000).	
	89	Abrignani et al., "Perspectives for a vaccine against hepatitis C virus," <i>Journal of Hepatology</i> , 31: (suppl. 1):259-263 (1999).	
	90	Bartenschlager et al., "Substrate Determinants for Cleavage in cis and in trans by the Hepatitis C Virus NS3 Proteinase," <i>Journal of Virology</i> , pp. 198 - 205, (1995).	
	91	Chen et al., "Detection of Hepatitis C Virus RNA in the Cell Fraction of Saliva Before and After Oral Surgery," <i>J. Med. Virol.</i> , 43:223-226 (1995).	
	92	Chen et al., "Human and Murine Antibody Recognition is Focused on the ATPase/Helicase, but not the Protease Domain of the Hepatitis C Virus Nonstructural 3 Protein," <i>Hepatology</i> , 28(1):219-224 (1998).	
	93	Chiang et al., "Enhancement of hepatitis C virus core antigen-specific type 1 T helper cell response by ribavirin correlates with the increased level of IL-2," <i>Vaccine Strategies Against Microbial Pathogens</i> , 42.11-42.16, p. A949 (date unknown).	
	94	Cotonat et al., "Pilot Study of Combination Therapy with Ribavirin and Interferon Alfa for the Retreatment of Chronic Hepatitis B e Antibody-Positive Patients," <i>Hepatology</i> , 31(2):502-506 (2000).	
	95	Cramp et al., "Hepatitis C Virus-Specific T-Cell Reactivity During Interferon and Ribavirin Treatment in Chronic Hepatitis C," <i>Gastron. Enterol.</i> , 118:346-355 (2000)	
	96	Diepolder et al., "Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection," <i>Lancet</i> , 346(8981):1006-1007.	
	97	Encke et al., "Genetic Immunization Generates Cellular and Humoral Immune Responses Against the Nonstructural Proteins of the Hepatitis C Virus in a Murine Model", <i>Journal of Immunology</i> , 161:4917-4923 (1998).	
	98	Fang et al., "Ribavirin enhancement of hepatitis C virus core antigen-specific type 1 T helper cell response correlates with the increased IL-12 level," <i>Journal of Hepatology</i> , 33(5):791-798 (2000).	
	99	Gordon et al., "Immune responses to hepatitis C virus structural and nonstructural proteins induced by plasmid DNA immunizations," <i>Journal of Infectious Diseases</i> , 181(1):42-50.	
	100	Grakoui et al., "A second hepatitis C virus-encoded proteinase," <i>Proc. Natl. Acad. Sci USA</i> , 90:10583-10587, (1993).	

Examiner Signature	Date Considered
--------------------	-----------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/817,591
	Filing Date	April 2, 2004
	First Named Inventor	Sallberg et al.
	Art Unit	1648
(Multiple sheets used when necessary)	Examiner	Bao Q. Li
SHEET 5 OF 7	Attorney Docket No.	TRIPEP.23AUS2C1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	101	Hsu et al., "Prospects for a Hepatitis C Virus Vaccine", <i>Clin Liver Dis</i> , 3(4):901-915 (1999).	
	102	http://www.msi.com/life/products/cerius2/modules/analogbuilder.html , C2Analog Builder, July 6, 2000.	
	103	Huffman et al., "In vitro effect of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (virazole, ICN 1229) on deoxyribonucleic acid and ribonucleic acid viruses," <i>Antimicrob. Agents. Chemother.</i> , 3(2):235 (1973).	
	104	Jin et al., "Expression, isolation, and characterization of the hepatitis C virus ATPase/RNA Helicase," <i>Arch. Biochem. Biophys.</i> , 323:47-53 (1995).	
	105	Kakumu et al., "Pilot Study of Ribarvirin and Interferon- for Chronic Hepatitis B," <i>Hepatology</i> , 18(2):258-263 (1993).	
	106	Kato, "Genome of human hepatitis C virus (HCV): gene organization, sequence diversity, and variation," <i>Microb. Com. Genomics</i> , 5(3):129-151 (2000).	
	107	Kumar et al, "Sequence, expression and reconstitution of an HCV genome from a British isolate derived from a single blood donation," <i>Journal of Viral Hepatitis</i> , 7:459-465 (2000).	
	108	Kwong et al., "Hepatitis C virus NS3/4A protease," <i>Antiviral Res.</i> , 41(1):67-84 (1999).	
	109	Kwong et al., "Structure and function of hepatitis C virus NS3 helicase," <i>Curr. Top. Microbiol. Immunol.</i> , 242:171-196 (2000).	
	110	Lawrence et al., "Advances in the treatment of hepatitis C," <i>Adv. Intern. Med.</i> , 45:65-105 (2000).	
	111	Li et al., "Role of the guanosine triphosphatase Rac2 in T helper 1 cell differentiation," <i>Science</i> , 288:2219-2222 (2000).	
	112	Marquardt et al., "Ribavirin inhibits mast cell mediator release," <i>J. Pharmacol. Exp. Therapeutics</i> , 240(1):145-149 (1987).	
	113	Marshall et al., "Detection of HCV RNA by the asymmetric gap ligase chain reaction," <i>PCR Methods and Applications</i> , 4(2):80-84 (1994).	
	114	Memar O. et al., "Antiviral Agents in Dermatology; Current Status and Future Prospects," <i>Internation Journal of Dermatology</i> , 34(9):597-606 (1995).	
	115	Missale et al., "Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response," <i>J. Clin. Invest.</i> , 98(3):706-714 (1996).	
	116	Neuberger et al., "Recombinant antibodies possessing novel effector functions," <i>Nature</i> , 312:604-608 (1984).	
	117	Pape et al., "Role of the specific T-cell response for clearance and control of hepatitis C virus," <i>J. Viral. Hepat.</i> , Supp. 6, 1:36-40 (1999).	
	118	Peavy et al., "Inhibition of murine plaque-forming cell responses in vivo by ribavirin," <i>J. Immunology</i> , 126(3):861-864 (1981).	
	119	Powers et al., "Selective inhibition of functional lymphocyte subpopulations by ribavirin," <i>Antimicrob. Agents. Chemother.</i> , 22(1):108-114 (1982).	

Examiner Signature	Date Considered
--------------------	-----------------

***Examiner:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/817,591
	Filing Date	April 2, 2004
	First Named Inventor	Sallberg et al.
	Art Unit	1648
(Multiple sheets used when necessary)	Examiner	Bao Q. Li
SHEET 6 OF 7	Attorney Docket No.	TRIPEP.23AUS2C1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	120	Proust B. et al., "Two Successive Hepatitis C Virus Infections in an Intravenous Drug User," <i>Journal of Clinical Microbiology</i> , 38(8):3125-3127 (2000).	
	121	Ramasamy et al., "Monocyclic L-Nucleosides with Type 1 Cytokine-Inducing Activity," <i>Journal of Medicinal Chemistry</i> , 43(5):1019-1028 (2000).	
	122	Sällberg and Hultgren, "Vaccines Containing Ribavirin and Methods of use Thereof," U.S. Patent Application Serial No. 10/104,966, filed March 22, 2002.	
	123	Sällberg et al., "Characterization of humoral and CD4+ cellular responses after genetic immunization with retroviral vectors expressing different forms of the hepatitis B virus core and e antigens," <i>Journal of Virology</i> , 71:5295-5303 (1997).	
	124	Sällberg, "A Hepatitis C Virus Non-Structural NS3/4A Fusion Gene," U.S. Patent Application Serial No. 09/930,591, filed August 15, 2001.	
	125	Schulof R. S., "Clinical, Virologic, and Immunologic Effects of Combination Therapy with Ribavirin and Isoprinostine in HIV-Infected Homosexual Men," <i>Journal of Acquired Immune Deficiency Syndromes</i> , 3(5):485-492 (1990).	
	126	Sidwell et al., "Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide," <i>Science</i> , 177(50):705-706 (1972).	
	127	Smith et al., "Molecular Engineering of the <i>Autographa californica</i> Nuclear Polyhedrosis Virus Genome: Deletion Mutations Within the Polyhedrin Gene," <i>Journal of Virology</i> , 46:584 (1983).	
	128	Spector et al., "The Antiviral Effect of Zidovudine and Ribavirin in Clinical Trials and the Use of p24 Antigen Levels as a Virologic Marker," <i>Journal of Infectious Diseases</i> , 159(5):822-828 (1989).	
	129	Szybalska and Szybalska, "Genetics of Human Cell Lines, IV. DNA-Mediated Heritable Transformation of a Biochemical Trait," <i>Proc Natl Acad Sci USA</i> , 48:2026 (1962).	
	130	Takeda et al., "Construction of chimaeric processed immunoglobulin genes containing mouse variable and human constant region sequences," <i>Nature</i> , 314:452-454 (1985).	
	131	Tam et al., "Ribavirin Polarizes Human T Cell Responses Towards a Type 1 Cytokine Profile," <i>Journal of Hepatology</i> , 30(3):376-382 (1999) (ABSTRACT).	
	132	Tam et al., "The Immunomodulatory effects of ribavirin: Recent findings," <i>International Antiviral News</i> , 7/6:99 - 100 (1999).	
	133	Tan et al., "How hepatitis C virus counteracts the interferon response: the jury is still out on NS5A," <i>Virology</i> , 284(1):1-12 (2001).	
	134	Vaitukaitis et al., "A method for producing specific antisera with small doses of immunogen," <i>J. Clin. Endocrinology Metab.</i> , 33(6):988-991 (1971).	
	135	Walsh et al., "Update on chronic viral hepatitis," <i>Postgrad Medical Journal</i> , 77(910):498-505 (2001).	
	136	Wang et al., "Synthesis and Cytokine Modulation Properties of Pyrrolo[2,3,-d]-4-pyrimidone Nucleosides," <i>J. Med. Chem.</i> , 43(13):2566-2574 (2000).	
	137	Zhang et al., "Characterization of a monoclonal antibody and its single-chain antibody fragment recognizing the nucleoside triphosphatase/helicase domain of the hepatitis C virus nonstructural 3 protein," <i>Clin. Diagn. Lab. Immunol.</i> , 7(1):58-63 (2000).	

Examiner Signature	Date Considered
--------------------	-----------------

***Examiner:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T¹ - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application No.	10/817,591
	Filing Date	April 2, 2004
	First Named Inventor	Sallberg et al.
	Art Unit	1648
(Multiple sheets used when necessary)	Examiner	Bao Q. Li
SHEET 7 OF 7	Attorney Docket No.	TRIPEP.23AUS2C1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	138	Zhang et al., "Molecular basis for antibody cross-reactivity between the hepatitis C virus core protein and the host-derived GOR protein," <i>Clin. Exp. Immunol.</i> , 96(3):403-409 (1994).	
	139	Zhang et al., "Interferon- α Treatment Induces Delayed CD4 Proliferative Responses to the Hepatitis C Virus Nonstructural Protein 3 Regardless of the Outcome of Therapy," <i>The Journal of Infectious Diseases</i> , 175:1294-1301 (1997).	

1851669
080505

Examiner Signature	Date Considered
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	

T¹ - Place a check mark in this area when an English language Translation is attached.